## Outcomes following Revision Osteochondral Allograft Transplantation of the Femoral Condyles at 5-Year Minimum Follow Up: A Matched Cohort Analysis

Zachary D Meeker<sup>1</sup>, Derrick Knapik, Kyle R Wagner, Ron Gilat, Eric J Cotter, Allen Ali Yazdi, Alexander Weissman, Adam Blair Yanke<sup>2</sup>, Brian J Cole<sup>3</sup>

<sup>1</sup>Orthopedics, <sup>2</sup>Rush University Med Ctr, <sup>3</sup>Rush University Medical Center INTRODUCTION:

Few studies have reported on midterm (5-year) outcomes following revision osteochondral allograft (OCA) transplantation. Therefore, the aim of this study is to investigate 5-year outcomes following revision OCA transplantation and compare outcomes with a matched control group of primary OCA patients. We hypothesize that patients undergoing revision OCA transplantation for the treatment of failed primary OCA transplantation will have improved patient-reported outcomes and similar survivorship free from failure when compared to those undergoing primary OCA.

METHODS: A retrospective review of prospectively collected data was performed to identify patients undergoing revision OCA transplantation of the femoral condyles between 1999-2018 with 5-year minimum follow up. A 1:2 cohort of matched primary OCA patients with respect to defect size, age, and body mass index (BMI) served as a control group. Lysholm, International Knee Documentation Committee (IKDC), and Knee Injury and Osteoarthritis Outcome Score (KOOS) subscales were collected, as well as reoperations or failures. Reoperation was defined as any subsequent surgery in the index compartment. Failure was defined as subsequent arthroplasty or revision cartilage procedure. Previously-determined thresholds for achieving clinically significant outcomes were utilized. RESULTS:

A total of 15 patients undergoing revision OCAs were successfully matched to 30 primary OCA patients and were followed for a mean  $9.3 \pm 3.0$  years (range: 5.1 - 14.7). Mean revision OCA patient age was  $31.1 \pm 9.7$  years (range: 19.9 - 52.7) with a mean BMI of  $25.9 \pm 3.4$  kg/m2 (range: 20.8 - 30.4). Lateral OCA was performed in 53% of cases (n = 8/15), while 73% (n = 11/15) underwent a concomitant procedure. The mean time between initial and revision OCA was  $2.9 \pm 1.4$  years (range: 1.2-6.2). Subsequent reoperation was performed in 60% (n = 9/15) of cases at a mean time of  $4.7 \pm 4.2$  years (range: 0.6 - 11.2) following revision OCA. Failures were observed in 13% (n = 2/15) of revision OCA patients, requiring total knee arthroplasty at a mean time of  $4.9 \pm 3.4$  years (range: 2.9 - 8.9). Survivorship free from reoperation (p = .568) and failure (p = .753) did not significantly differ between primary and revision groups. At 5-year minimum, patient acceptable symptomatic state (PASS) was achieved by a majority of revision OCA patients for IKDC (70%), Lysholm (83%), and KOOS subset questionnaires (Symptoms [70%], Pain [100%], Activities of Daily Living [80%], Sport [90%], and Quality of Life [80%]).

DISCUSSION AND CONCLUSION: At a mean follow up of 9.3 years, 67% of patients undergoing revision OCA required reoperation, with 13% undergoing arthroplasty. Survivorship free from failure and reoperation was not different between those undergoing primary or revision OCA. Achievement of PASS was observed for multiple outcome measures in those undergoing revision OCA. The primary finding from this investigation was that revision OCA demonstrates improvement in clinical outcomes and durability at minimum 5-year follow up. While reoperation rates approach 50% at 10 years, overall conversion to arthroplasty rates remains low at mid-term follow up. Survivorship free from reoperation and failure did not significantly differ from a matched cohort of those who underwent primary OCA. Therefore, our hypothesis was confirmed, as patients undergoing revision OCA had clinical improvement and comparable survivorship free from reoperation and failure compared to primary OCA patients.




Table 1: Demographics and Intrasperative Variables Revision Osteochendral Allograft Transplantation, 5-Year Minimum Follow-Up				
Variable	Primary OCA, a = 30	Revision OCA, a = 15	P-valu	
Sex			0.277	
Female	17 (57%)	11 (73%)		
Male	13 (43%)	4 (27%)		
Age (years)			0.516	
Mean = SD	28.7 = 9.0	31.4 ± 10.0		
вмі			0.838	
Mean ± SD	26.17 ± 3.24	25.90 ± 3.43		
Laterality			0.028	
Left	14 (47%)	2 (13%)		
Right	16 (53%)	13 (87%)		
Smoking status			>0.999	
Current	1 (3.3%)	1 (6.7%)		
Former	1 (3.3%)	0 (0%)		
	28 (92%)	14 (99%)		
WC	2 (6.7%)	1 (6.7%)	>0.99	
Prior surgeries			<0.001	
Mean + SD	2.80 ± 1.40	5.60 ± 1.59		
Symptom duration (years)	5.6 ± 6.4	5.5 ± 5.6	0.904	
Defect width (mm)			0.917	
Mean + SD	20.18 ± 2.57	20.10 ± 2.58		
MFC	8 (27%)	7 (47%)	0.190	
LFC	22 (73%)	8 (53%)	0.256	
Major Concomitant Surgery	22 (73%)	11 (73%)	>0.999	
LMTs	16 (53%)	5 (33%)	0.205	
MMTv	4/19%)	3 (20%)	0.670	

Variable	Primary	Revision	p-value <sup>2</sup>
Saseline scores			
IKBC	43.4 ± 17.7	41.5 ± 15.0	0.423
Lysholm	47.8 ± 17.0	45.0 ± 17.2	0.114
KOOS subscales			
Pain	60.2 ± 16.7	53.0 ± 17.3	0.151
Symptoms	56.7 ± 14.1	57.8 ± 19.8	0.746
Sport	33.8 ± 28.8	33.6 ± 23.6	0.506
ADL.	66.3 ± 19.3	71.4 = 21.3	0.676
QOL	21.1 ± 19.2	30.4 ± 19.5	0.494
5-year minimum so	sres		
IKBC	75.7 ± 16.1	72.4 ± 15.5	0.552
Lysholm	85.1 ± 7.8	78.8 ± 7.8	0.229

Characteristic	Primary	Revision	P-value
Subjective IKDC	7 / 9 (78%)	7 / 10 (70%)	>0.999
Lysholm	8 / 8 (100%)	57.6 (83%)	0.429
Pain	7 / 9 (78%)	10 / 10 (100%)	0.211
Symptoms	5 / 9 (56%)	7 / 10 (70%)	0.650
Speet	7 / 9 (78%)	9 / 10 (90%)	0.582
ADL	3 / 9 (33%)	8 / 10 (80%)	0.070
oor	9 / 9 (100%)	8 / 10 (80%)	0.582
categorical variables listed	as n/N		